Clinical_JJ and_CC Epidemiological_JJ Relevance_NN of_IN Quantitating_NP Hepatitis_NP E_NP Virus-Specific_NP Immunoglobulin_NP M_NP Diagnosis_NN of_IN acute_JJ hepatitis_NN E_NN by_IN detection_NN of_IN hepatitis_NP E_NP virus_NN (HEV)-specific_JJ immunoglobulin_NN M_NP (_( IgM_NP )_) is_VBZ an_DT established_JJ procedure_NN ._SENT We_PP investigated_VBD whether_IN quantitation_NN of_IN HEV_NP IgM_NP and_CC its_PP$ ratio_NN to_TO HEV_NP total_NN Ig_NP furnished_VBD more_JJR information_NN than_IN conventional_JJ IgM_NP tests_NNS that_WDT are_VBP interpreted_VBN as_IN positive_JJ or_CC negative_JJ ._SENT A_DT previously_RB described_VBN indirect_JJ immunoassay_NN for_IN total_JJ Ig_NP against_IN a_DT baculovirus-expressed_JJ HEV_NP capsid_NN protein_NN was_VBD modified_VBN to_TO quantitate_VB HEV-specific_NP IgM_NP in_IN Walter_NP Reed_NP (_( WR_NP )_) antibody_NN units_NNS by_IN using_VBG a_DT reference_NN antiserum_NN and_CC the_DT four-parameter_NN logistic_JJ model_NN ._SENT A_DT receiver-operating_VBG characteristics_NNS curve_NN derived_VBN from_IN 197_CD true-positive_JJ specimens_NNS and_CC 449_CD true-negative_JJ specimens_NNS identified_VBD 30_CD WR_NP units/ml_NN as_IN an_DT optimum_JJ cut_NN point_NN ._SENT The_DT median_JJ HEV_NP IgM_NP level_NN in_IN 36_CD patients_NNS with_IN acute_JJ hepatitis_NP E_NP fell_VBD from_IN 3,000_CD to_TO 100_CD WR_NP units/ml_NN over_IN 6_CD months_NNS ,_, suggesting_VBG that_IN 100_CD WR_NP units/ml_NN would_MD be_VB a_DT more_RBR appropriate_JJ cut_NN point_NN for_IN distinguishing_VBG recent_JJ from_IN remote_JJ IgM_NP responses_NNS ._SENT Among_IN three_CD hepatitis_NN E_NN case_NN series_NN ,_, determination_NN of_IN the_DT HEV_NP IgM-to-total-Ig_NP ratio_NN in_IN acute-phase_NN serum_NN revealed_VBD that_IN most_JJS patients_NNS had_VBD high_JJ ratios_NNS consistent_JJ with_IN primary_JJ infections_NNS whereas_IN a_DT few_JJ had_VBD low_JJ ratios_NNS ,_, suggesting_VBG that_IN they_PP had_VBD sustained_VBN reinfections_NNS that_WDT elicited_VBD anamnestic_JJ antibody_NN responses_NNS ._SENT The_DT diagnostic_JJ utility_NN of_IN the_DT new_JJ IgM_NP test_NN was_VBD similar_JJ to_TO that_DT of_IN a_DT commercially_RB available_JJ test_NN that_WDT uses_VBZ different_JJ HEV_NP antigens_NNS ._SENT In_IN conclusion_NN ,_, we_PP found_VBD that_IN HEV_NP IgM_NP can_MD be_VB detected_VBN specifically_RB in_IN >95_JJ %_NN of_IN acute_JJ hepatitis_NN E_NN cases_NNS defined_VBN by_IN detection_NN of_IN the_DT virus_NN genome_NN in_IN serum_NN and_CC that_DT quantitation_NN of_IN HEV_NP IgM_NP and_CC its_PP$ ratio_NN to_TO total_VB Ig_NP provides_VBZ insight_NN into_IN infection_NN timing_NN and_CC prior_JJ immunity_NN ._SENT Hepatitis_NP E_NP is_VBZ acute_JJ ,_, self-limited_JJ hepatitis_NN caused_VBN by_IN a_DT virus_NN of_IN the_DT same_JJ name_NN (_( hepatitis_NP E_NP virus_NN [_SYM HEV_NP ]_SYM )_) that_WDT is_VBZ excreted_VBN in_IN feces_NN and_CC transmitted_VBD orally_RB ._SENT In_IN large_JJ parts_NNS of_IN Asia_NP and_CC Africa_NP ,_, this_DT disease_NN is_VBZ common_JJ ,_, causing_VBG sporadic_JJ and_CC epidemic_JJ illness_NN ._SENT Diagnosis_NN of_IN acute_JJ hepatitis_NN E_NN is_VBZ based_VBN on_IN detection_NN of_IN the_DT HEV_NP genome_NN in_IN serum_NN or_CC feces_NN by_IN reverse_JJ transcription-PCR_NN (_( RT-PCR_NP )_) or_CC detection_NN of_IN newly_RB elicited_VBN antibodies_NNS to_TO HEV_NP ,_, in_IN particular_JJ HEV-specific_NP immunoglobulin_NN M_NP (_( IgM_NP )_) ._SENT An_DT IgM_NP test_NN is_VBZ marketed_VBN in_IN Asia_NP ;_: this_DT test_NN uses_VBZ recombinant_JJ HEV_NP antigens_NNS derived_VBN from_IN the_DT carboxyl_NN terminus_NN of_IN the_DT capsid_NN protein_NN (_( ORF-2_NP )_) and_CC ORF-3_NP ._SENT The_DT good_JJ diagnostic_JJ utility_NN of_IN the_DT marketed_VBN test_NN has_VBZ been_VBN characterized_VBN ._SENT Moreover_RB ,_, several_JJ research_NN laboratories_NNS have_VBP developed_VBN IgM_NP tests_NNS based_VBN on_IN alternative_JJ recombinant_JJ HEV_NP (_( rHEV_NP )_) antigens_NNS expressed_VBN in_IN bacteria_NNS or_CC by_IN use_NN of_IN the_DT baculovirus_NN system_NN ._SENT Recently_RB ,_, we_PP reported_VBD an_DT indirect_JJ enzyme_NN immunoassay_NN (_( EIA_NP )_) for_IN total_JJ Ig_NP against_IN a_DT baculovirus-expressed_JJ HEV_NP capsid_NN protein_NN that_IN quantitated_JJ antibodies_NNS to_TO HEV_NP in_IN Walter_NP Reed_NP (_( WR_NP )_) antibody_NN units_NNS by_IN using_VBG a_DT reference_NN antiserum_NN and_CC the_DT four-parameter_NN logistic_JJ model_NN ._SENT We_PP modified_VBD this_DT test_NN to_TO detect_VB HEV-specific_NP IgM_NP and_CC employed_VBN the_DT IgM_NP and_CC total-Ig_NP tests_NNS together_RB to_TO characterize_VB serum_NN specimens_NNS from_IN patients_NNS with_IN suspected_JJ acute_JJ hepatitis_NP E._NP We_PP investigated_VBD whether_IN quantitation_NN of_IN HEV_NP IgM_NP and_CC its_PP$ ratio_NN to_TO HEV_NP total_JJ Ig_NP furnished_JJ more_RBR diagnostic_JJ or_CC epidemiological_JJ information_NN than_IN conventional_JJ IgM_NP tests_NNS that_WDT are_VBP interpreted_VBN as_IN positive_JJ or_CC negative_JJ ._SENT Here_RB we_PP report_VBP the_DT development_NN of_IN an_DT HEV_NP IgM_NP quantitation_NN standard_NN ,_, the_DT protocol_NN for_IN the_DT IgM_NP test_NN ,_, the_DT kinetics_NN of_IN HEV_NP IgM_NP and_CC total-Ig_NP responses_NNS over_IN 6_CD months_NNS in_IN a_DT case_NN series_NN of_IN patients_NNS with_IN hepatitis_NP E_NP ,_, an_DT extensive_JJ characterization_NN of_IN the_DT test_NN 's_POS sensitivity_NN and_CC specificity_NN ,_, the_DT use_NN of_IN the_DT IgM-to-total-Ig_NP ratio_NN to_TO identify_VB rare_JJ cases_NNS of_IN clinically_RB overt_JJ reinfection_NN ,_, and_CC our_PP$ test_NN 's_POS good_JJ concordance_NN with_IN the_DT marketed_VBN IgM_NP test_NN ._SENT We_PP found_VBD that_DT quantitation_NN of_IN IgM_NP and_CC total_JJ Ig_NP together_RB furnished_VBD novel_JJ insight_NN into_IN infection_NN timing_NN and_CC prior_JJ immunity_NN ._SENT RT-PCR_NP ._SENT |_SYM Serum_NP specimens_NNS were_VBD tested_VBN for_IN the_DT HEV_NP genome_NN ,_, indicating_VBG viremia_NN during_IN acute_JJ infection_NN ,_, by_IN use_NN of_IN previously_RB published_VBN protocols_NNS that_WDT detect_VBP either_CC a_DT conserved_VBN region_NN of_IN ORF1_NP or_CC ORF2_NP ._SENT The_DT previously_RB unpublished_JJ HEV_NP ORF2_NP nested_VBD PCR_NP primers_NNS ,_, designated_VBN set_VBD 3_CD ,_, are_VBP listed_VBN in_IN Table_NP ._SENT Reference_IN human_JJ antibodies_NNS ._SENT |_SYM Equal_NP aliquots_NNS of_IN acute-phase_NN serum_NN from_IN 20_CD hepatitis_NN E_NN patients_NNS from_IN Nepal_NP were_VBD pooled_VBN ;_: each_DT case_NN was_VBD diagnosed_VBN by_IN detection_NN of_IN HEV_NP viremia_NN by_IN RT-PCR_NP ._SENT Pool_NN 6_CD ,_, created_VBN by_IN diluting_VBG the_DT acute-phase_NN serum_NN pool_NN with_IN approximately_RB 3_CD volumes_NNS of_IN serum_NN with_IN HEV-specific_JJ total-Ig_NN levels_NNS of_IN <0.1_JJ WR_NP unit/ml_NN ,_, was_VBD designated_VBN the_DT HEV_NP IgM_NP quantitation_NN standard_NN ._SENT Pool_NN 7_CD ,_, created_VBN by_IN diluting_VBG pool_NN 6_CD with_IN approximately_RB 3_CD more_JJR volumes_NNS of_IN the_DT same_JJ negative_JJ serum_NN ,_, was_VBD designated_VBN the_DT IgM_NP positive_JJ control_NN ._SENT Relative_JJ potency_NN ._SENT |_SYM The_DT relative_JJ potencies_NNS of_IN reference_NN antisera_NN and_CC working_VBG antigen_NN lots_NNS were_VBD determined_VBN by_IN parallel_JJ line_NN assay_NN and_CC calculation_NN of_IN a_DT common_JJ slope_NN ,_, as_RB previously_RB described_VBN ._SENT rHEV_NP antigens_NNS ._SENT |_SYM The_DT antigen_NN for_IN all_DT assays_NNS was_VBD a_DT 56-kDa_NP recombinant_JJ capsid_NN protein_NN truncated_VBN at_IN the_DT amino_NN and_CC carboxyl_NN ends_VBZ to_TO comprise_VB amino_NN acids_NNS 112_CD to_TO 607_CD of_IN the_DT 660-amino-acid_JJ protein_NN ._SENT The_DT protein_NN ,_, made_VBN in_IN Spodoptera_NP frugiperda_NP cells_NNS by_IN using_VBG a_DT baculovirus_NN expression_NN vector_NN ,_, was_VBD prepared_VBN by_IN Novavax_NP as_IN previously_RB described_VBN ._SENT All_DT tests_NNS used_VBD 33_CD WR_NP antigen_NN units/ml_NN ;_: antigens_NNS were_VBD from_IN one_CD of_IN the_DT lots_NNS previously_RB characterized_VBN ._SENT EIA_NP protocols_NNS ._SENT |_SYM The_DT IgM_NP assay_NN protocol_NN was_VBD identical_JJ to_TO the_DT total-Ig_NN protocol_NN except_IN that_WDT the_DT goat_NN anti-human_NP Ig-horseradish_NP peroxidase_NN (_( HRP_NP )_) conjugate_VBP was_VBD replaced_VBN with_IN goat_NN anti-human_NP IgM-HRP_NP (_( Kirkegaard_NP and_CC Perry_NP )_) ._SENT The_DT optimal_JJ 1:4,000_CD dilution_NN of_IN anti-IgM_NN conjugate_JJ was_VBD determined_VBN by_IN testing_VBG twofold_JJ dilutions_NNS to_TO find_VB the_DT highest_JJS signal-to-noise_NN ratio_NN ._SENT Serum_NN specimens_NNS ._SENT |_SYM Serum_NP specimens_NNS stripped_VBN of_IN personal_JJ identifiers_NNS were_VBD from_IN archives_NN at_IN the_DT Walter_NP Reed_NP Army_NP Institute_NP of_IN Research_NP (_( WRAIR_NP ,_, Silver_NP Spring_NP ,_, Md._NP )_) and_CC the_DT Armed_NP Forces_NPS Research_NP Institute_NP of_IN Medical_NP Sciences_NPS (_( Bangkok_NP ,_, Thailand_NP )_) ._SENT All_DT were_VBD from_IN volunteers_NNS enrolled_VBN in_IN research_NN protocols_NNS approved_VBN by_IN local_JJ institutional_JJ review_NN boards_NNS and_CC the_DT Human_NP Subjects_NP Research_NP Review_NP Board_NP of_IN the_DT U.S._NP Army_NP Surgeon_NP General_NP ._SENT The_DT majority_NN of_IN hepatitis_NP E_NP serum_NN specimens_NNS came_VBD from_IN three_CD consecutive_JJ case_NN series_NN in_IN Nepal_NP :_: pregnant_JJ women_NNS enrolled_VBN in_IN an_DT observational_JJ cohort_NN study_NN ,_, a_DT cross-sectional_JJ study_NN of_IN intrafamilial_JJ HEV_NP transmission_NN that_WDT identified_VBD hepatitis_NP E_NP patients_NNS and_CC subclinical_JJ infections_NNS in_IN persons_NNS domiciled_VBN with_IN them_PP ,_, and_CC surveillance_NN of_IN hepatitis_NN E_NN among_IN soldiers_NNS ._SENT IgM_NP EIA_NP control_NN parameters_NNS ._SENT |_SYM Control_NP parameters_NNS were_VBD developed_VBN to_TO ensure_VB accuracy_NN and_CC consistency_NN ._SENT Eighteen_CD wells_NNS on_IN each_DT 96-well_NN plate_NN were_VBD utilized_VBN for_IN the_DT following_VBG duplicate_JJ controls_NNS :_: six_CD half-log_NN dilutions_NNS of_IN the_DT HEV_NP IgM_NP quantitation_NN standard_NN (_( pool_NN 6_CD )_) ,_, the_DT positive_JJ control_NN (_( pool_NN 7_CD )_) ,_, the_DT same_JJ negative_JJ control_NN as_IN for_IN the_DT total-Ig_NN test_NN ,_, and_CC a_DT no-serum_NN control_NN ._SENT Thirty_CD consecutive_JJ technically_RB adequate_JJ runs_NNS were_VBD used_VBN to_TO calculate_VB limits_NNS for_IN control_NN parameters_NNS as_IN the_DT mean_JJ +-_NN 1.96_CD (_( standard_NN deviation_NN )_) of_IN log-transformed_JJ values_NNS (_( expressed_VBN as_IN optical_JJ density_NN [_SYM OD_NP ]_SYM or_CC WR_NP units_NNS per_IN milliliter_NN ,_, as_RB appropriate_JJ )_) ._SENT Thereafter_RB ,_, assays_NNS were_VBD accepted_VBN according_VBG to_TO these_DT limits_NNS ._SENT Quantitation_NP ._SENT |_SYM In_IN using_VBG the_DT four-parameter_NN logistic_JJ model_NN for_IN quantitation_NN ,_, accuracy_NN is_VBZ greatest_JJS at_IN the_DT midpoint_NN of_IN the_DT standard_JJ curve_NN and_CC least_JJS at_IN the_DT lower_JJR and_CC upper_JJ limits_NNS ._SENT We_PP used_VBD the_DT procedures_NNS for_IN quantitation_NN developed_VBN for_IN the_DT total-Ig_NN test_NN (_( testing_VBG in_IN duplicate_JJ ,_, OD_JJ limits_NNS prompting_VBG sample_NN dilution_NN and_CC retesting_NN )_) to_TO ensure_VB consistency_NN ._SENT Comparison_NN of_IN antibody_NN potency_NN by_IN WRAIR_NP and_CC Genelabs_NP Technologies_NPS IgM_NP EIAs_NP ._SENT |_SYM To_TO characterize_VB the_DT relationship_NN between_IN antibody_NN potency_NN determined_VBN by_IN the_DT WRAIR_NP IgM_NP EIA_NP and_CC that_IN determined_VBN by_IN a_DT widely_RB used_VBN commercial_JJ test_NN (_( HEV_NP IgM_NP enzyme-linked_JJ immunosorbent_JJ assay_NN ;_: Genelabs_NP Technologies_NPS ,_, Singapore_NP )_) ,_, we_PP tested_VBD dilutions_NNS of_IN three_CD specimens_NNS in_IN both_DT tests_NNS ._SENT The_DT commercial_JJ test_NN employs_VBZ a_DT mixture_NN of_IN recombinant_JJ HEV_NP ORF2_NP and_CC ORF3_NP polypeptides_NNS expressed_VBD in_IN Escherichia_NP coli_NNS which_WDT are_VBP absent_JJ from_IN the_DT WRAIR_NP test_NN 's_POS 56-kDa_NP rHEV_NP capsid_NN antigen_NN and_CC the_DT ORF2_NP polypeptide_NN SG3_NP (_( amino_NN acids_NNS 334_CD to_TO 660_CD )_) ,_, also_RB expressed_VBN in_IN E._NP coli_NNS ,_, which_WDT overlaps_VBZ 53_CD %_NN of_IN the_DT 56-kDa_NP rHEV_NP capsid_NN antigen_NN ._SENT The_DT commercial-test_NN results_NNS were_VBD expressed_VBN in_IN OD_JJ units_NNS ,_, whereas_IN WRAIR_NP EIA_NP results_NNS were_VBD expressed_VBN in_IN WR_NP units_NNS per_IN milliliter_NN ._SENT Three_CD regression_NN lines_NNS were_VBD derived_VBN ,_, and_CC the_DT portions_NNS of_IN each_DT titration_NN curve_NN above_IN each_DT assay_NN 's_POS cut_NN point_NN were_VBD compared_VBN ._SENT Additionally_RB ,_, serial_JJ serum_NN specimens_NNS from_IN six_CD patients_NNS with_IN hepatitis_NP E_NP confirmed_VBD by_IN detection_NN of_IN HEV_NP viremia_NNS were_VBD tested_VBN in_IN both_DT assays_NNS ,_, and_CC their_PP$ results_NNS were_VBD compared_VBN ._SENT TABLE_NN 1_CD |_SYM HEV_NP ORF2_NP "_'' set_NN 3_CD "_'' nested_VBD PCR_NP primers_NNS Potency_NN of_IN reference_NN antibodies_NNS ._SENT |_SYM As_RB previously_RB described_VBN ,_, we_PP quantified_VBD HEV-specific_JJ total_JJ Ig_NP by_IN using_VBG arbitrary_JJ WR_NP units_NNS per_IN milliliter_NN defined_VBN by_IN a_DT convalescent-phase_NN reference_NN serum_NN (_( pool_NN 4_CD )_) ._SENT We_PP chose_VBD to_TO quantify_VB HEV_NP IgM_NP also_RB by_IN using_VBG WR_NP units_NNS per_IN milliliter_NN ,_, in_IN this_DT case_NN by_IN an_DT IgM_NP quantitation_NN standard_NN called_VBD pool_NN 6_CD ,_, arbitrarily_RB defined_VBN to_TO contain_VB 860_CD WR_NP units_NNS of_IN HEV_NP IgM/ml_NP ._SENT The_DT relationship_NN between_IN a_DT unit_NN of_IN HEV_NP IgM_NP and_CC a_DT unit_NN of_IN HEV_NP total_JJ Ig_NP is_VBZ undefined_JJ ,_, but_CC these_DT units_NNS are_VBP roughly_RB equivalent_JJ ,_, as_IN pool_NN 6_CD ,_, defined_VBN to_TO contain_VB 860_CD WR_NP units_NNS of_IN HEV_NP IgM/ml_NP ,_, was_VBD determined_VBN to_TO contain_VB 820_CD WR_NP units_NNS of_IN HEV_NP total_JJ Ig/ml_NP by_IN parallel_JJ line_NN assay_NN against_IN pool_NN 4_CD ._SENT Dilutions_NNS of_IN pool_NN 6_CD were_VBD used_VBN on_IN each_DT assay_NN plate_NN to_TO establish_VB an_DT IgM_NP standard_NN curve_NN ._SENT Pool_NN 7_CD also_RB was_VBD used_VBN on_IN every_DT assay_NN plate_NN as_IN an_DT IgM_NP positive_JJ control_NN ._SENT EIA_NP control_NN parameters_NNS and_CC assay_NN stability_NN ._SENT |_SYM To_TO ensure_VB EIA_NP accuracy_NN and_CC consistency_NN ,_, we_PP empirically_RB set_VBD control_NN parameters_NNS and_CC used_VBN individual_JJ plate_NN standards_NNS and_CC controls_NNS ._SENT These_DT control_NN parameters_NNS were_VBD derived_VBN from_IN 30_CD consecutive_JJ technically_RB adequate_JJ assays_NNS ._SENT The_DT limited_JJ variation_NN of_IN these_DT parameters_NNS over_IN those_DT 30_CD assays_NNS is_VBZ evidence_NN that_IN a_DT skilled_JJ serologist_NN can_MD achieve_VB consistent_JJ assay_NN performance_NN ._SENT Kinetics_NNS of_IN IgM_NP and_CC total-Ig_NP responses_NNS in_IN patients_NNS with_IN hepatitis_NP E._NP |_SYM Consecutive_JJ patients_NNS with_IN suspected_JJ acute_JJ viral_JJ hepatitis_NN hospitalized_VBN at_IN one_CD center_NN in_IN Nepal_NP were_VBD evaluated_VBN for_IN hepatitis_NP E_NP by_IN an_DT RT-PCR_NP test_NN for_IN viremia_NN ._SENT Thirty-six_NP cases_NNS of_IN hepatitis_NP E_NP were_VBD identified_VBN ,_, and_CC HEV_NP IgM_NP and_CC total-Ig_NP levels_NNS were_VBD determined_VBN for_IN four_CD serial_JJ serum_NN specimens_NNS from_IN each_DT of_IN these_DT patients_NNS collected_VBN over_IN approximately_RB 6_CD months_NNS ._SENT The_DT initial_JJ geometric_JJ mean_JJ IgM_NP level_NN was_VBD 3,000_CD WR_NP units/ml_NN at_IN a_DT median_NN of_IN 8_CD days_NNS after_IN illness_NN onset_NN ;_: the_DT level_NN declined_VBD slightly_RB over_IN the_DT next_JJ 2_CD weeks_NNS and_CC then_RB exponentially_RB over_IN the_DT next_JJ 5_CD months_NNS ,_, nevertheless_RB remaining_VBG easily_RB detectable_JJ at_IN 100_CD WR_NP units/ml_NN at_IN a_DT median_NN of_IN 190_CD days_NNS after_IN illness_NN onset_NN ._SENT Geometric_JJ mean_JJ total_NN Ig_NP against_IN HEV_NP was_VBD greater_JJR than_IN IgM_NP at_IN every_DT time_NN point_NN analyzed_VBD ,_, as_RB was_VBD expected_VBN ,_, but_CC the_DT decline_NN in_IN total_JJ Ig_NP mirrored_VBD that_IN in_IN IgM_NP ._SENT IgM_NP test_NN sensitivity_NN ,_, specificity_NN ,_, and_CC cut_NN point_NN ._SENT |_SYM After_IN determining_VBG the_DT range_NN of_IN IgM_NP levels_NNS likely_JJ to_TO occur_VB among_IN patients_NNS ,_, we_PP analyzed_VBD the_DT performance_NN of_IN the_DT IgM_NP test_NN in_IN order_NN to_TO identify_VB a_DT cut_NN point_NN ._SENT Specificity_NN was_VBD assessed_VBN with_IN serum_NN specimens_NNS from_IN 449_CD persons_NNS at_IN low_JJ risk_NN for_IN acute_JJ HEV_NP infection_NN ;_: these_DT were_VBD considered_VBN true-negative_JJ specimens_NNS ._SENT Approximately_RB two-thirds_NNS were_VBD from_IN healthy_JJ persons_NNS of_IN all_DT ages_NNS ,_, including_VBG some_DT residing_VBG in_IN Nepal_NP ,_, a_DT country_NN where_WRB hepatitis_NP E_NP is_VBZ endemic_JJ ._SENT Specimens_NNS from_IN Nepal_NP residents_NNS were_VBD collected_VBN several_JJ months_NNS before_IN the_DT annual_JJ epidemic_NN ,_, when_WRB the_DT monthly_JJ infection_NN rate_NN is_VBZ <2_JJ per_IN 10,000_CD (_( M._NP P._NP Shrestha_NP and_CC R._NP M._NP Scott_NP ,_, unpublished_JJ data_NNS )_) ._SENT Other_JJ healthy_JJ donors_NNS were_VBD from_IN the_DT United_NP States_NPS or_CC Thailand_NP ,_, where_WRB hepatitis_NP E_NP is_VBZ not_RB endemic_JJ ._SENT Additionally_RB ,_, about_IN one-third_NN of_IN the_DT true-negative_JJ specimens_NNS were_VBD from_IN patients_NNS in_IN Thailand_NP recently_RB infected_VBD with_IN bacteria_NNS or_CC viruses_NNS other_JJ than_IN HEV_NP that_IN cause_NN hepatitis_NN ._SENT The_DT distribution_NN of_IN HEV_NP IgM_NP levels_NNS detected_VBD in_IN this_DT negative_JJ specimen_NN set_NN is_VBZ shown_VBN in_IN the_DT upper_JJ histogram_NN of_IN Fig._NN ._SENT Most_JJS values_NNS were_VBD between_IN 1_CD and_CC 16_CD WR_NP units/ml_NN ._SENT Sensitivity_NN was_VBD assessed_VBN with_IN serum_NN specimens_NNS from_IN 197_CD persons_NNS with_IN acute_JJ hepatitis_NN E_NN infection_NN diagnosed_VBN by_IN detection_NN of_IN HEV_NP viremia_NN ._SENT Of_IN these_DT ,_, 94_CD %_NN had_VBD clinically_RB overt_JJ hepatitis_NN E_NN ,_, while_IN 6_CD %_NN had_VBD had_VBN subclinical_JJ infections_NNS ._SENT These_DT patients_NNS were_VBD predominantly_RB from_IN Nepal_NP ;_: a_DT few_JJ were_VBD from_IN Indonesia_NP or_CC Bangladesh_NP ;_: all_DT had_VBD their_PP$ specimens_NNS submitted_VBN to_TO our_PP$ laboratories_NNS for_IN serologic_JJ diagnosis_NN ._SENT The_DT distribution_NN of_IN HEV_NP IgM_NP levels_NNS detected_VBD in_IN this_DT positive_JJ specimen_NN set_NN is_VBZ shown_VBN in_IN the_DT lower_JJR histogram_NN of_IN Fig._NN ._SENT Most_JJS values_NNS were_VBD between_IN 200_CD and_CC 20,000_CD WR_NP units/ml_NN ._SENT A_DT receiver-operating_VBG characteristics_NNS curve_NN was_VBD constructed_VBN from_IN the_DT test_NN results_NNS described_VBD above_RB by_IN using_VBG cut_NN points_NNS of_IN 10_CD ,_, 20_CD ,_, 30_CD ,_, 40_CD ,_, 60_CD ,_, and_CC 100_CD WR_NP units/ml_NN ._SENT A_DT cut_NN point_NN of_IN 30_CD WR_NP units/ml_NN combines_VBZ maximal_JJ sensitivity_NN and_CC specificity_NN ._SENT Nevertheless_RB ,_, because_IN elevated_JJ HEV_NP IgM_NP levels_NNS appear_VBP to_TO persist_VB for_IN 6_CD months_NNS after_IN illness_NN onset_NN ,_, a_DT cut_NN point_NN of_IN 100_CD WR_NP units/ml_NN seems_VBZ more_RBR appropriate_JJ for_IN distinguishing_VBG recent_JJ from_IN remote_JJ infection_NN ._SENT Among_IN the_DT 36_CD cases_NNS for_IN which_WDT data_NNS are_VBP summarized_VBN in_IN Fig._NN ,_, the_DT proportion_NN with_IN HEV_NP IgM_NP levels_NNS above_IN the_DT cut_NN point_NN of_IN 100_CD WR_NP units/ml_NN fell_VBD from_IN 92_CD %_NN within_IN 3_CD weeks_NNS of_IN illness_NN onset_NN to_TO 83_CD %_NN at_IN 8_CD weeks_NNS after_IN onset_NN and_CC 53_CD %_NN at_IN 6_CD months_NNS after_IN illness_NN onset_NN ._SENT Ratio_NN of_IN HEV_NP IgM_NP to_TO total_VB Ig_NP ._SENT |_SYM We_PP determined_VBD the_DT ratio_NN of_IN HEV_NP IgM_NP to_TO total_VB Ig_NP for_IN all_DT 197_CD serum_NN specimens_NNS in_IN the_DT true-positive_JJ specimen_NN set_NN ._SENT The_DT histogram_NN of_IN those_DT results_NNS shows_VBZ that_IN most_JJS values_NNS were_VBD between_IN 0.1_CD and_CC 10_CD and_CC were_VBD distributed_VBN symmetrically_RB around_IN a_DT median_JJ value_NN of_IN 1.0_CD ._SENT Nevertheless_RB ,_, <5_JJ %_NN of_IN specimens_NNS (_( n_NN =_SYM 8_CD )_) had_VBD distinctly_RB low_JJ ratios_NNS ,_, such_JJ that_IN these_DT specimens_NNS appeared_VBD to_TO constitute_VB a_DT separate_JJ population_NN ._SENT Serology_NN data_NNS for_IN acute-phase_NN and_CC early-convalescent-phase_NN serum_NN specimens_NNS from_IN cases_NNS representing_VBG the_DT 25th_JJ ,_, 50th_JJ ,_, and_CC 75th_JJ percentiles_NNS were_VBD compared_VBN to_TO data_NNS from_IN the_DT eight_CD outlying_JJ cases_NNS with_IN markedly_RB low_JJ HEV_NP IgM-to-total-Ig_NP ratios_NNS ._SENT All_DT patients_NNS had_VBD HEV_NP viremia_NNS demonstrated_VBN in_IN the_DT first_JJ specimens_NNS ._SENT Of_IN the_DT eight_CD outlying_JJ cases_NNS ,_, seven_CD represented_VBD patients_NNS with_IN clinically_RB overt_JJ hepatitis_NN E_NN whereas_IN one_CD case_NN was_VBD an_DT inapparent_JJ infection_NN detected_VBN in_IN a_DT family_NN member_NN of_IN a_DT patient_NN with_IN hepatitis_NP E._NP The_DT timing_NN of_IN the_DT first_JJ specimen_NN collection_NN after_IN illness_NN onset_NN for_IN these_DT eight_CD cases_NNS was_VBD similar_JJ to_TO ,_, or_CC even_RB earlier_RBR than_IN ,_, that_IN for_IN the_DT 25th-_JJ ,_, 50th-_JJ ,_, and_CC 75th-percentile_JJ cases_NNS ,_, excluding_VBG late_JJ collection_NN as_IN an_DT explanation_NN for_IN low_JJ IgM_NP levels_NNS ._SENT Nevertheless_RB ,_, there_EX are_VBP striking_JJ contrasts_NNS :_: among_IN the_DT eight_CD cases_NNS with_IN low_JJ IgM-to-Ig_NP ratios_NNS ,_, the_DT levels_NNS of_IN IgM_NP are_VBP low_JJ and_CC the_DT levels_NNS of_IN total_JJ Ig_NP are_VBP extremely_RB high_JJ ._SENT These_DT findings_NNS suggest_VBP that_IN typical_JJ cases_NNS of_IN hepatitis_NP E_NP represent_VBP primary_JJ infections_NNS with_IN a_DT typical_JJ evolution_NN of_IN Ig_NP isotypes_NNS from_IN IgM_NP to_TO IgG_NP ,_, whereas_IN a_DT minority_NN of_IN cases_NNS represent_VBP reinfection_NN (_( secondary_JJ infections_NNS )_) ,_, with_IN a_DT typical_JJ anamnestic_JJ Ig_NP response_NN characterized_VBN by_IN low_JJ levels_NNS of_IN IgM_NP and_CC extremely_RB high_JJ levels_NNS of_IN IgG_NP ._SENT Comparison_NN of_IN WRAIR_NP and_CC Genelabs_NP Technologies_NPS IgM_NP EIAs_NP ._SENT |_SYM We_PP found_VBD a_DT consistent_JJ and_CC highly_RB correlated_VBN relationship_NN between_IN antibody_NN binding_VBG assessment_NN by_IN the_DT WRAIR_NP IgM_NP EIA_NP and_CC that_IN by_IN a_DT commercial_JJ test_NN widely_RB available_JJ in_IN Asia_NP ,_, for_IN pool_NN 6_CD and_CC for_IN acute-phase_NN serum_NN specimens_NNS from_IN two_CD typical_JJ hepatitis_NN E_NN cases_NNS in_IN Nepal_NP ._SENT Nevertheless_RB ,_, a_DT proportion_NN of_IN each_DT titration_NN curve_NN was_VBD to_TO the_DT right_NN of_IN the_DT WRAIR_NP cut_NN point_NN (_( 30_CD WR_NP units/ml_NP )_) (_( i.e._FW ,_, positive_JJ )_) but_CC below_IN the_DT Genelabs_NP cut_NN point_NN (_( i.e._FW ,_, negative_JJ )_) ._SENT The_DT greater_JJR sensitivity_NN of_IN the_DT WRAIR_NP test_NN for_IN low_JJ levels_NNS of_IN antibody_NN may_MD confer_VB some_DT advantage_NN on_IN that_DT test_NN ._SENT The_DT relative_JJ utility_NN of_IN the_DT two_CD tests_NNS was_VBD compared_VBN directly_RB in_IN a_DT sample_NN of_IN 19_CD specimens_NNS collected_VBN at_IN varying_VBG intervals_NNS after_IN disease_NN onset_NN (_( median_JJ of_IN 40_CD days_NNS of_IN follow-up_NN after_IN disease_NN onset_NN )_) from_IN six_CD hepatitis_NN E_NN patients_NNS diagnosed_VBN by_IN detection_NN of_IN viremia_NN ._SENT All_DT specimens_NNS were_VBD positive_JJ in_IN both_DT tests_NNS ._SENT A_DT line_NN plot_NN of_IN results_NNS for_IN each_DT case_NN ,_, determined_VBN by_IN the_DT WRAIR_NP test_NN (_( Fig._NN ,_, upper_JJ graph_NN )_) and_CC the_DT Genelabs_NP test_NN (_( Fig._NN ,_, lower_JJR graph_NN )_) ,_, shows_VBZ that_IN the_DT kinetic_JJ responses_NNS were_VBD similar_JJ in_IN four_CD cases_NNS and_CC different_JJ in_IN two_CD (_( cases_NNS 7_CD and_CC 10_CD )_) ._SENT Overall_RB ,_, the_DT performance_NN of_IN the_DT two_CD tests_NNS appeared_VBD similar_JJ ._SENT FIG._NN 1_CD ._SENT |_SYM Plots_NP of_IN the_DT HRP_NP conjugate_JJ and_CC of_IN positive_JJ (_( pool_NN 7_CD )_) ,_, negative_JJ ,_, and_CC no-serum_NN (_( antigen_NN )_) controls_VBZ over_IN 30_CD technically_RB adequate_JJ assays_NNS ._SENT Plots_NNS of_IN the_DT HRP_NP conjugate_JJ and_CC of_IN positive_JJ (_( pool_NN 7_CD )_) ,_, negative_JJ ,_, and_CC no-serum_NN (_( antigen_NN )_) controls_VBZ over_IN 30_CD technically_RB adequate_JJ assays_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Levels_NP of_IN HEV_NP IgM_NP (_( solid_JJ line_NN )_) and_CC total_JJ Ig_NP (_( dashed_VBN line_NN )_) among_IN 36_CD patients_NNS with_IN hepatitis_NN E_NN proven_VBN by_IN detection_NN of_IN HEV_NP viremia_NN ._SENT Levels_NNS of_IN HEV_NP IgM_NP (_( solid_JJ line_NN )_) and_CC total_JJ Ig_NP (_( dashed_VBN line_NN )_) among_IN 36_CD patients_NNS with_IN hepatitis_NN E_NN proven_VBN by_IN detection_NN of_IN HEV_NP viremia_NN ._SENT Each_DT patient_NN had_VBD four_CD consecutive_JJ serum_NN specimens_NNS collected_VBD ._SENT Data_NNS are_VBP grouped_VBN by_IN median_JJ day_NN of_IN specimen_NN collection_NN ;_: these_DT values_NNS plus_IN the_DT associated_VBN interquartile_NN ranges_NNS in_IN parentheses_NNS are_VBP given_VBN below_IN the_DT plot_NN of_IN HEV_NP IgM_NP ._SENT Error_NN bars_NNS represent_VBP the_DT 95_CD %_NN confidence_NN interval_NN for_IN the_DT geometric_JJ mean_NN ._SENT Horizontal_JJ dotted_JJ reference_NN lines_NNS are_VBP drawn_VBN at_IN 30_CD and_CC 100_CD WR_NP units/ml_NN ._SENT The_DT table_NN below_IN the_DT line_NN plot_NN gives_VBZ the_DT proportions_NNS of_IN patients_NNS with_IN HEV_NP IgM_NP detected_VBD at_IN four_CD median_JJ time_NN points_NNS for_IN assay_NN cut_NN points_NNS of_IN 100_CD and_CC 30_CD WR_NP units/ml_NN ._SENT FIG._NN 3_CD ._SENT |_SYM (_( Top_JJ )_) Histogram_NN of_IN HEV_NP IgM_NP levels_NNS determined_VBN in_IN a_DT true-negative_JJ specimen_NN set_VBN (_( n_NN =_SYM 449_CD )_) ._SENT (_( Top_JJ )_) Histogram_NN of_IN HEV_NP IgM_NP levels_NNS determined_VBN in_IN a_DT true-negative_JJ specimen_NN set_VBN (_( n_NN =_SYM 449_CD )_) ._SENT The_DT interval_NN scale_NN is_VBZ logarithmic_JJ ;_: the_DT mode_NN is_VBZ 6_CD WR_NP units/ml_NN ._SENT Vertical_JJ dotted_JJ reference_NN lines_NNS are_VBP drawn_VBN at_IN 30_CD and_CC 100_CD WR_NP units/ml_NN ._SENT (_( Bottom_JJ )_) Histogram_NN of_IN HEV_NP IgM_NP levels_NNS determined_VBN in_IN a_DT true-positive_JJ specimen_NN set_VBN (_( n_NN =_SYM 197_CD )_) ._SENT The_DT interval_NN scale_NN is_VBZ logarithmic_JJ ;_: the_DT mode_NN is_VBZ 2,512_CD WR_NP units/ml_NN ._SENT Vertical_JJ dotted_JJ reference_NN lines_NNS are_VBP drawn_VBN at_IN 30_CD and_CC 100_CD WR_NP units/ml_NN ._SENT FIG._NN 4_CD ._SENT |_SYM Receiver-operating_VBG characteristic_JJ plot_NN for_IN IgM_NP EIA_NP based_VBN on_IN true-negative_JJ and_CC true-positive_JJ specimen_NN sets_NNS ._SENT Receiver-operating_VBG characteristic_JJ plot_NN for_IN IgM_NP EIA_NP based_VBN on_IN true-negative_JJ and_CC true-positive_JJ specimen_NN sets_NNS ._SENT FIG._NN 5_CD ._SENT |_SYM Histogram_NN of_IN HEV_NP IgM-to-total-Ig_NP ratios_NNS for_IN the_DT true-positive_JJ specimen_NN set_VBN (_( n_NN =_SYM 197_CD )_) ._SENT Histogram_NN of_IN HEV_NP IgM-to-total-Ig_NP ratios_NNS for_IN the_DT true-positive_JJ specimen_NN set_VBN (_( n_NN =_SYM 197_CD )_) ._SENT The_DT interval_NN scale_NN is_VBZ logarithmic_JJ ;_: the_DT mode_NN is_VBZ 1.6_CD ._SENT Vertical_JJ reference_NN lines_NNS mark_VBP cumulative_JJ distribution_NN percentiles_NNS ,_, as_RB follows_VBZ :_: dotted_JJ lines_NNS ,_, 5_CD and_CC 95_CD %_NN ;_: solid_JJ lines_NNS ,_, 25_CD and_CC 75_CD %_NN ;_: dashed-and-dotted_JJ line_NN ,_, 50_CD %_NN ._SENT Cases_NNS to_TO the_DT right_NN of_IN the_DT 5_CD %_NN reference_NN line_NN (_( n_NN =_SYM 189_CD )_) appear_VBP to_TO represent_VB primary_JJ infections_NNS ,_, whereas_IN cases_NNS to_TO the_DT left_NN of_IN the_DT 5_CD %_NN reference_NN line_NN (_( n_NN =_SYM 8_CD )_) appear_VBP to_TO represent_VB secondary_JJ infections_NNS with_IN anamnestic_JJ antibody_NN responses_NNS ._SENT FIG._NN 6_CD ._SENT |_SYM Comparison_NP of_IN IgM_NP quantitation_NN by_IN WRAIR_NP and_CC Genelabs_NP Technologies_NPS EIAs_NP ._SENT Comparison_NN of_IN IgM_NP quantitation_NN by_IN WRAIR_NP and_CC Genelabs_NP Technologies_NPS EIAs_NP ._SENT Titration_NN of_IN three_CD acute-phase_NN serum_NN specimens_NNS from_IN hepatitis_NP E_NP patients_NNS is_VBZ represented_VBN ._SENT Horizontal_JJ dotted_JJ reference_NN line_NN ,_, cut_VBD point_NN for_IN the_DT Genelabs_NP test_NN ;_: vertical_JJ dotted_JJ reference_NN line_NN ,_, cut_NN point_NN (_( 30_CD WR_NP units/ml_NN )_) for_IN the_DT WRAIR_NP test_NN ._SENT FIG._NN 7_CD ._SENT |_SYM Serial_JJ determinations_NNS of_IN HEV_NP IgM_NP levels_NNS for_IN six_CD patients_NNS with_IN acute_JJ hepatitis_NN E_NN confirmed_VBN by_IN RT-PCR_NP detection_NN of_IN HEV_NP viremia_NN in_IN the_DT initial_JJ specimen_NN ._SENT Serial_JJ determinations_NNS of_IN HEV_NP IgM_NP levels_NNS for_IN six_CD patients_NNS with_IN acute_JJ hepatitis_NN E_NN confirmed_VBN by_IN RT-PCR_NP detection_NN of_IN HEV_NP viremia_NN in_IN the_DT initial_JJ specimen_NN ._SENT The_DT upper_JJ graph_NN shows_VBZ results_NNS obtained_VBN by_IN using_VBG the_DT WRAIR_NP IgM_NP test_NN ;_: the_DT bottom_JJ graph_NN shows_VBZ results_NNS obtained_VBN by_IN using_VBG the_DT Genelabs_NP Diagnostics_NP test_NN ._SENT All_DT 19_CD specimens_NNS were_VBD positive_JJ in_IN each_DT test_NN ._SENT The_DT cut_NN point_NN for_IN each_DT test_NN is_VBZ shown_VBN as_IN a_DT dashed_VBN line_NN ._SENT TABLE_NN 2_CD |_SYM IgM_NP EIA_NP control_NN parameters_NNS defined_VBN by_IN their_PP$ variation_NN over_IN 30_CD consecutive_JJ assays_NNS TABLE_NP 3_CD |_SYM Composition_NN of_IN the_DT true-negative_JJ specimen_NN set_VBN (_( n_NN =_SYM 449_CD )_) TABLE_NP 4_CD |_SYM Serology_NN data_NNS for_IN all_DT secondary_JJ cases_NNS and_CC representative_JJ primary_JJ cases_NNS of_IN hepatitis_NP E_NP in_IN a_DT sample_NN of_IN 197_CD patients_NNS from_IN areas_NNS where_WRB hepatitis_NP E_NP is_VBZ endemic_JJ We_PP have_VBP adapted_VBN our_PP$ previously_RB reported_VBN indirect_JJ EIA_NP ,_, which_WDT is_VBZ able_JJ to_TO quantitate_VB HEV_NP total_JJ Ig_NP accurately_RB and_CC reproducibly_RB ,_, to_TO quantitate_VB HEV_NP IgM_NP ._SENT This_DT is_VBZ the_DT third_JJ report_NN describing_VBG an_DT IgM_NP EIA_NP that_WDT uses_VBZ a_DT recombinant_JJ HEV_NP capsid_NN protein_NN expressed_VBN in_IN the_DT baculovirus_NN system_NN ,_, but_CC the_DT first_JJ HEV_NP IgM_NP test_NN to_TO offer_VB quantitation_NN or_CC to_TO be_VB so_RB exhaustively_RB characterized_VBN ._SENT The_DT performance_NN of_IN the_DT IgM_NP test_NN was_VBD extensively_RB evaluated_VBN ,_, and_CC assay_NN specificity_NN ,_, sensitivity_NN ,_, and_CC consistency_NN were_VBD carefully_RB documented_VBN ._SENT We_PP used_VBD the_DT IgM_NP and_CC previously_RB described_VBD total-Ig_NN tests_NNS to_TO determine_VB HEV_NP IgM_NP levels_NNS ,_, total-Ig_NN levels_NNS ,_, and_CC their_PP$ ratio_NN in_IN acute-phase_JJ serum_NN specimens_NNS from_IN almost_RB 200_CD cases_NNS of_IN hepatitis_NP E_NP occurring_VBG in_IN countries_NNS where_WRB hepatitis_NP E_NP is_VBZ endemic_JJ ._SENT This_DT dual_JJ testing_NN allowed_VBD us_PP to_TO make_VB the_DT novel_JJ observation_NN that_IN a_DT small_JJ proportion_NN of_IN disease_NN is_VBZ characterized_VBN by_IN an_DT anamnestic_JJ antibody_NN response_NN ,_, suggesting_VBG that_IN these_DT cases_NNS result_NN from_IN secondary_JJ infection_NN of_IN a_DT person_NN who_WP had_VBD previously_RB recovered_VBN from_IN a_DT primary_JJ infection_NN ._SENT We_PP chose_VBD an_DT indirect_JJ EIA_NP format_NN for_IN detecting_VBG and_CC quantitating_VBG HEV_NP IgM_NP despite_IN its_PP$ inferior_JJ specificity_NN compared_VBN to_TO an_DT IgM_NP isotype-capture_NN EIA_NP ._SENT We_PP rejected_VBD developing_VBG an_DT IgM_NP isotype-capture_NN EIA_NP after_IN initial_JJ experiments_NNS demonstrated_VBD poor_JJ sensitivity_NN despite_IN use_NN of_IN substantially_RB greater_JJR amounts_NNS of_IN the_DT rHEV_NP antigen_NN ._SENT We_PP inferred_VBD from_IN this_DT observation_NN that_IN the_DT rHEV_NN antigen_NN ,_, in_IN the_DT physical_JJ form_NN used_VBN in_IN this_DT assay_NN (_( thawed_VBN from_IN -70C_NN storage_NN one_CD to_TO three_CD times_NNS before_IN use_NN )_) and_CC at_IN concentrations_NNS that_WDT were_VBD economically_RB feasible_JJ ,_, was_VBD inefficient_JJ at_IN bridging_VBG layers_NNS of_IN specific_JJ Ig_NP ._SENT This_DT behavior_NN of_IN our_PP$ rHEV_NP antigen_NN limited_VBD the_DT assay_NN format_NN to_TO an_DT indirect_JJ test_NN ._SENT One_CD of_IN the_DT weaknesses_NNS of_IN an_DT indirect_JJ test_NN is_VBZ that_IN IgM-rheumatoid_NP factor_NN in_IN a_DT test_NN serum_NN ,_, which_WDT has_VBZ activity_NN against_IN the_DT Fc_NP portion_NN of_IN IgG_NP directed_VBD against_IN HEV_NP antigen_NN ,_, may_MD elicit_VB a_DT false-positive_JJ result_NN ._SENT We_PP substantially_RB reduced_VBD the_DT risk_NN of_IN such_JJ nonspecific_JJ reactions_NNS by_IN testing_VBG serum_NN initially_RB diluted_VBN 1:1,000_CD ._SENT The_DT other_JJ potential_JJ weakness_NN of_IN an_DT indirect_JJ EIA_NP format_NN is_VBZ reduced_VBN sensitivity_NN due_JJ to_TO competition_NN between_IN virus-specific_JJ IgM_NP and_CC IgG_NP for_IN antigen_NN binding_VBG sites_NNS ._SENT The_DT test_NN sensitivity_NN of_IN 92_CD to_TO 97_CD %_NN ,_, depending_VBG on_IN the_DT cut_NN point_NN ,_, suggests_VBZ that_IN IgG_NP competition_NN is_VBZ not_RB a_DT limitation_NN of_IN this_DT particular_JJ assay_NN ._SENT A_DT necessary_JJ step_NN in_IN developing_VBG the_DT quantitative_JJ IgM_NP EIA_NP was_VBD the_DT creation_NN of_IN reference_NN antibody_NN pools_NNS of_IN HEV_NP IgM_NP by_IN using_VBG human_JJ serum_NN from_IN Nepal_NP ,_, where_WRB hepatitis_NP E_NP is_VBZ endemic_JJ ._SENT By_IN trial_NN and_CC error_NN ,_, we_PP set_VBD the_DT potency_NN of_IN the_DT IgM_NP quantitation_NN standard_NN so_RB that_IN a_DT WR_NP unit_NN of_IN IgM_NP and_CC a_DT WR_NP unit_NN of_IN total_JJ Ig_NP (_( M_NP plus_CC G_NP plus_CC A_DT isotypes_NNS )_) were_VBD comparable_JJ ._SENT There_EX is_VBZ no_DT international_JJ HEV_NP IgM_NP reference_NN standard_NN ,_, as_IN the_DT available_JJ World_NP Health_NP Organization_NP HEV_NP antibody_NN standard_NN contains_VBZ only_RB low_JJ levels_NNS of_IN HEV-specific_NP IgM_NP (_( 105.6_CD WR_NP units/ml_NN )_) ._SENT We_PP can_MD provide_VB samples_NNS of_IN our_PP$ IgM_NP and_CC total-Ig_NP reference_NN standards_NNS (_( available_JJ from_IN the_DT Department_NP of_IN Virus_NP Diseases_NPS ,_, WRAIR_NP ,_, upon_IN request_NN )_) to_TO interested_JJ laboratories_NNS who_WP wish_VBP to_TO prepare_VB their_PP$ own_JJ in-house_JJ standards_NNS ._SENT Of_IN the_DT several_JJ approaches_NNS for_IN EIA_NP quantitation_NN of_IN an_DT unknown_NN by_IN using_VBG a_DT standard_JJ curve_NN ,_, we_PP chose_VBD the_DT four-parameter_NN logistic_JJ model_NN ,_, which_WDT is_VBZ generally_RB considered_VBN the_DT most_RBS accurate_JJ and_CC reproducible_JJ ._SENT We_PP retained_VBD all_DT procedures_NNS from_IN our_PP$ total-Ig_NN test_NN ,_, previously_RB shown_VBN to_TO be_VB reproducibly_RB accurate_JJ to_TO below_IN the_DT cut_NN point_NN (_( 7_CD %_NN median_JJ error_NN in_IN quantitation_NN of_IN the_DT mid-range_JJ standard_NN )_) ._SENT To_TO achieve_VB accurate_JJ and_CC reproducible_JJ quantitation_NN ,_, an_DT operator_NN must_MD perform_VB this_DT test_NN with_IN great_JJ care_NN ,_, using_VBG well-controlled_JJ reagents_NNS ._SENT This_DT is_VBZ more_RBR likely_JJ to_TO be_VB possible_RB when_WRB the_DT test_NN is_VBZ performed_VBN routinely_RB ,_, as_RB might_MD be_VB expected_VBN in_IN a_DT research_NN serology_NN laboratory_NN or_CC a_DT regional_JJ or_CC national_JJ public_JJ health_NN laboratory_NN ._SENT We_PP had_VBD access_NN to_TO serial_JJ serum_NN specimens_NNS collected_VBN over_IN 6_CD months_NNS from_IN 36_CD hepatitis_NN E_NN patients_NNS ._SENT These_DT specimens_NNS demonstrated_VBD that_IN IgM_NP antibody_NN levels_NNS were_VBD very_RB high_JJ soon_RB after_IN illness_NN onset_NN ,_, declined_VBD little_RB over_IN several_JJ weeks_NNS ,_, and_CC then_RB declined_VBD rapidly_RB to_TO low_JJ levels_NNS over_IN the_DT next_JJ 4_CD to_TO 6_CD months_NNS ._SENT This_DT is_VBZ typical_JJ of_IN IgM_NP responses_NNS to_TO other_JJ acute_JJ ,_, self-limited_JJ ,_, systemic_JJ viral_JJ infections_NNS ._SENT The_DT weeks-long_JJ duration_NN of_IN markedly_RB elevated_JJ IgM_NP levels_NNS after_IN disease_NN onset_NN means_VBZ that_IN diagnosis_NN using_VBG even_RB relatively_RB insensitive_JJ IgM_NP detection_NN methods_NNS should_MD be_VB successful_JJ ,_, even_RB if_IN patients_NNS come_VBN to_TO medical_JJ attention_NN late_RB ._SENT Moreover_RB ,_, the_DT months-long_JJ duration_NN of_IN IgM_NP responses_NNS to_TO HEV_NP may_MD be_VB a_DT boon_NN to_TO hepatitis_NP E_NP outbreak_NN investigations_NNS ,_, since_IN these_DT typically_RB commence_VBP months_NNS after_IN the_DT index_NN case_NN occurs_VBZ ._SENT A_DT sensitive_JJ IgM_NP test_NN should_MD be_VB able_JJ to_TO identify_VB most_JJS disease_NN cases_NNS from_IN late-convalescent-phase_JJ serum_NN specimens_NNS ;_: the_DT WRAIR_NP test_NN meets_VBZ this_DT criterion_NN by_IN detecting_VBG HEV_NP IgM_NP above_IN a_DT cut_NN point_NN of_IN 30_CD WR_NP units/ml_NN in_IN 92_CD %_NN of_IN specimens_NNS collected_VBD a_DT median_NN of_IN 2_CD months_NNS after_IN disease_NN onset_NN and_CC in_IN 83_CD %_NN of_IN specimens_NNS collected_VBD 6_CD months_NNS after_IN disease_NN onset_NN ._SENT Additionally_RB ,_, since_IN many_JJ HEV_NP infections_NNS are_VBP known_VBN to_TO be_VB subclinical_JJ ,_, sensitive_JJ tests_NNS for_IN IgM_NP may_MD enable_VB identification_NN of_IN all_DT infected_JJ persons_NNS rather_RB than_IN those_DT with_IN disease_NN only_RB ._SENT The_DT preceding_JJ paragraph_NN illustrates_VBZ some_DT of_IN the_DT ways_NNS in_IN which_WDT an_DT HEV_NP IgM_NP test_NN might_MD be_VB used_VBN ._SENT For_IN different_JJ uses_NNS ,_, different_JJ assay_NN cut_NN points_NNS may_MD be_VB appropriate_JJ ._SENT The_DT receiver-operating_VBG characteristics_NNS curve_NN identified_VBD 30_CD WR_NP units/ml_NN as_IN the_DT cut_NN point_NN suitable_JJ for_IN outbreak_NN investigations_NNS ,_, in_IN which_WDT it_PP is_VBZ necessary_JJ to_TO find_VB remotely_RB infected_JJ persons_NNS ,_, whereas_IN it_PP identified_VBD 100_CD WR_NP units/ml_NN as_IN a_DT marginally_RB less_RBR sensitive_JJ cut_NN point_NN that_WDT could_MD distinguish_VB a_DT recent_JJ infection_NN from_IN a_DT remote_JJ one_CD ._SENT We_PP began_VBD this_DT study_NN anticipating_VBG that_IN an_DT HEV_NP IgM_NP test_NN would_MD improve_VB serological_JJ diagnosis_NN of_IN hepatitis_NP E_NP ,_, then_RB based_VBN on_IN detection_NN of_IN HEV-specific_NP total_JJ Ig_NP or_CC IgG_NP ._SENT We_PP confirmed_VBD that_DT detection_NN of_IN HEV_NP IgM_NP is_VBZ the_DT best_RBS serological_JJ test_NN for_IN diagnosis_NN of_IN hepatitis_NP E._NP Yet_CC the_DT most_RBS interesting_JJ aspect_NN of_IN our_PP$ work_NN was_VBD the_DT observation_NN that_IN in_IN some_DT cases_NNS of_IN hepatitis_NP E_NP ,_, there_EX was_VBD a_DT weak_JJ or_CC absent_JJ IgM_NP response_NN ._SENT By_IN combining_VBG HEV_NP IgM_NP and_CC total-Ig_NP tests_NNS ,_, we_PP identified_VBD primary_JJ and_CC anamnestic_JJ HEV_NP immune_JJ responses_NNS among_IN adolescent_JJ and_CC adult_JJ hepatitis_NN E_NN patients_NNS in_IN areas_NNS of_IN HEV_NP endemicity_NN ,_, distinguished_VBN by_IN widely_RB divergent_JJ HEV_NP IgM-to-total-Ig_NP ratios_NNS ._SENT We_PP inferred_VBD that_IN anamnestic_JJ responses_NNS resulted_VBN from_IN reinfection_NN (_( secondary_JJ infection_NN )_) of_IN a_DT person_NN having_VBG an_DT immunologic_JJ memory_NN of_IN prior_JJ HEV_NP infection_NN ._SENT In_IN our_PP$ experience_NN ,_, secondary_JJ infections_NNS are_VBP uncommon_JJ ,_, comprising_VBG <5_JJ %_NN of_IN overt_JJ hepatitis_NN E_NN cases_NNS ._SENT This_DT is_VBZ an_DT important_JJ observation_NN because_IN previously_RB ,_, some_DT authorities_NNS have_VBP speculated_VBN that_IN waning_VBG immunity_NN explained_VBD why_WRB most_JJS cases_NNS of_IN hepatitis_NP E_NP occurred_VBD among_IN adults_NNS ._SENT The_DT fact_NN that_IN more_JJR than_IN 90_CD %_NN of_IN hepatitis_NP E_NP cases_NNS in_IN areas_NNS of_IN HEV_NP endemicity_NN occur_VBP in_IN patients_NNS who_WP have_VBP a_DT primary_JJ antibody_NN response_NN refutes_VBZ this_DT speculation_NN of_IN waning_VBG immunity_NN ,_, since_IN previously_RB exposed_VBN persons_NNS should_MD mount_VB an_DT anamnestic_JJ response_NN upon_IN reexposure_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, we_PP do_VBP speculate_VB that_IN asymptomatic_JJ secondary_JJ infections_NNS may_MD be_VB more_RBR common_JJ than_IN symptomatic_JJ ones_NNS ._SENT Ultimately_RB ,_, the_DT true_JJ prevalence_NN of_IN secondary_JJ infection_NN and_CC disease_NN must_MD be_VB assessed_VBN prospectively_RB ._SENT Such_JJ studies_NNS also_RB may_MD identify_VB the_DT risk_NN factors_NNS that_WDT are_VBP associated_VBN with_IN partial_JJ failure_NN of_IN immunity_NN and_CC determine_VB whether_IN clinical_JJ outcomes_NNS differ_VBP between_IN primary_JJ and_CC secondary_JJ disease_NN ._SENT If_IN secondary_JJ disease_NN is_VBZ associated_VBN with_IN high-dose_NN HEV_NP exposure_NN or_CC waning_VBG immunity_NN ,_, hepatitis_NP E_NP vaccines_NNS now_RB under_IN development_NN may_MD have_VB public_JJ health_NN utility_NN even_RB among_IN previously_RB exposed_VBN persons_NNS ,_, if_IN they_PP can_MD be_VB demonstrated_VBN to_TO boost_VB protective_JJ immunity_NN ._SENT Finally_RB ,_, we_PP wanted_VBD to_TO evaluate_VB the_DT WRAIR_NP IgM_NP test_NN against_IN the_DT test_NN marketed_VBD widely_RB in_IN Asia_NP by_IN Genelabs_NP Diagnostics_NP ._SENT The_DT comparison_NN was_VBD initiated_VBN by_IN testing_NN in_IN parallel_JJ serial_JJ dilutions_NNS of_IN three_CD acute-phase_NN specimens_NNS using_VBG the_DT WRAIR_NP and_CC Genelabs_NP Diagnostics_NP tests_NNS ._SENT We_PP found_VBD that_IN the_DT tests_NNS performed_VBD similarly_RB across_IN a_DT range_NN of_IN dilutions_NNS ,_, suggesting_VBG that_IN these_DT tests_NNS were_VBD comparable_JJ for_IN serological_JJ diagnosis_NN of_IN acute_JJ disease_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT results_NNS suggested_VBD that_IN the_DT WRAIR_NP test_NN would_MD be_VB more_RBR versatile_JJ in_IN outbreak_NN investigations_NNS based_VBN on_IN its_PP$ apparent_JJ superiority_NN at_IN detecting_VBG low_JJ levels_NNS of_IN IgM_NP reflecting_VBG remote_JJ infection_NN ._SENT The_DT comparison_NN was_VBD completed_VBN by_IN testing_VBG a_DT separate_JJ panel_NN of_IN 19_CD specimens_NNS from_IN 6_CD hepatitis_NN E_NN patients_NNS with_IN viremia_NN by_IN both_DT tests_NNS ._SENT In_IN this_DT limited_JJ assessment_NN ,_, both_CC tests_NNS sensitively_RB detected_VBD true_JJ acute_JJ HEV_NP disease_NN over_IN a_DT median_NN of_IN 40_CD days_NNS of_IN follow-up_NN ._SENT This_DT result_NN is_VBZ consistent_JJ with_IN an_DT earlier_JJR report_NN by_IN Ghabrah_NP and_CC others_NNS ,_, who_WP found_VBD 96_CD %_NN concordance_NN (_( kappa_NN ,_, 0.87_CD )_) between_IN an_DT IgM_NP test_NN using_VBG an_DT antigen_NN similar_JJ to_TO that_DT used_VBN in_IN the_DT WRAIR_NP test_NN and_CC the_DT Genelabs_NP IgM_NP test_NN ._SENT In_IN conclusion_NN ,_, the_DT test_NN method_NN described_VBD here_RB enables_VBZ accurate_JJ quantitation_NN of_IN HEV_NP IgM_NP ,_, including_VBG low_JJ levels_NNS associated_VBN with_IN remote_JJ infection_NN ._SENT Detection_NN of_IN HEV_NP IgM_NP is_VBZ the_DT method_NN of_IN choice_NN for_IN laboratory_NN diagnosis_NN of_IN hepatitis_NP E._NP By_IN combining_VBG quantitation_NN of_IN HEV_NP IgM_NP and_CC total-Ig_NP levels_NNS ,_, a_DT new_JJ class_NN of_IN secondary_JJ infections_NNS can_MD be_VB detected_VBN ._SENT The_DT epidemiological_JJ implications_NNS of_IN secondary_JJ infections_NNS are_VBP clear_JJ ,_, but_CC their_PP$ clinical_JJ implications_NNS must_MD be_VB assessed_VBN ._SENT 